Busto, FranciscoSepúlveda, HugoPrieto, Catalina P.Carrasco, MargaritaDíaz, LorenaPalma, JoséLattus, JoséMontecino, MartínPalma, Verónica2023-10-232023-10-232017-12Stem Cells Volume 35, Issue 12, Pages 2430 - 2441December 20171066-5099https://repositorio.unab.cl/xmlui/handle/ria/53557Indexación: ScopusNovel bone regeneration approaches aim to obtain immature osteoblasts from somatic stem cells. Umbilical cord Wharton's jelly mesenchymal stem cells (WJ-MSCs) are an ideal source for cell therapy. Hence, the study of mechanisms involved in WJ-MSC osteoblastic differentiation is crucial to exploit their developmental capacity. Here, we have assessed epigenetic control of the Runt-related transcription factor 2 (RUNX2) osteogenic master regulator gene in WJ-MSC. We present evidence indicating that modulation of RUNX2 expression through preventing Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase activity is relevant to enhance WJ-MSC osteoblastic potential. Hence, JARID1B loss of function in WJ-MSC results in increased RUNX2/p57 expression. Our data highlight JARID1B activity as a novel target to modulate WJ-MSC osteoblastic differentiation with potential applications in bone tissue engineering. Stem Cells 2017;35:2430–2441. © 2017 AlphaMed PressenEpigeneticsMesenchymal stem cells (MSCs)OsteoblastsUmbilical cordArtículoCC BY-NC-ND 4.0 DEED10.1002/stem.2704